Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvation Bio, Inc.

7.15
+2.3548.96%
Post-market: 7.240.0900+1.26%19:37 EST
Volume:59.10M
Turnover:401.13M
Market Cap:2.45B
PE:-11.17
High:7.35
Open:4.99
Low:4.94
Close:4.80
52wk High:7.35
52wk Low:1.54
Shares:342.83M
Float Shares:231.05M
Volume Ratio:8.06
T/O Rate:25.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6400
EPS(LYR):-2.1131
ROE:-52.49%
ROA:-24.82%
PB:7.52
PE(LYR):-3.38

Loading ...

Nuvation Bio Shares Have Room to Run on Ibtrozi Momentum, Wedbush Says

MT Newswires Live
·
4 hours ago

Nuvation Bio price target raised to $11 from $7 at Wedbush

TIPRANKS
·
6 hours ago

Nuvation Bio Shares Surge After B. Riley Initiates Coverage at Buy

MT Newswires Live
·
7 hours ago

Nuvation Bio Up Nearly 41%, on Track for Record Percent Increase -- Data Talk

Dow Jones
·
8 hours ago

Nuvation Bio initiated with a Buy at B. Riley

TIPRANKS
·
Yesterday

U.S. RESEARCH ROUNDUP-Amgen, Crowdstrike, Micron Technology

Reuters
·
Yesterday

Nuvation Bio Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $12

THOMSON REUTERS
·
Yesterday

Nuvation Bio (NUVB): Assessing Valuation Following Q3 Results and Capital Raise Plans

Simply Wall St.
·
Nov 15

Stock Track | Nuvation Bio Plummets 5.38% as New Commercialization Risks Emerge for Taletrectinib

Stock Track
·
Nov 05

Nuvation Bio’s Strategic Dilemma: Navigating Taletrectinib’s Global Commercialization Risks

TIPRANKS
·
Nov 05

Stock Track | Nuvation Bio Tumbles 5.18% as Q3 Results Show Widening Losses Despite Revenue Beat

Stock Track
·
Nov 05

Stock Track | Nuvation Bio Plummets 13.29% Pre-market Despite Q3 Revenue Beat as Losses Widen and Expenses Surge

Stock Track
·
Nov 04

Stock Track | Nuvation Bio Plummets 13.29% as Q3 Results Reveal Widening Losses Despite Revenue Beat

Stock Track
·
Nov 04

Nuvation Bio Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 04

RBC Raises Price Target on Nuvation Bio to $8 From $7, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Nov 04

Stock Track | Nuvation Bio Plunges 5.22% Pre-market Despite Q3 Revenue Beat as Losses Widen and Expenses Surge

Stock Track
·
Nov 04

Stock Track | Nuvation Bio Plunges 6.96% Despite Better-than-Expected Q3 Revenue as Losses Widen

Stock Track
·
Nov 04

Stock Track | Nuvation Bio Plunges 6.96% Despite Q3 Revenue Beat as Losses Widen

Stock Track
·
Nov 04

Nuvation Bio (NUVB) Gets a Buy from TD Cowen

TIPRANKS
·
Nov 04

GUIDANCE: (NUVB) Nuvation Bio Posts Q3 Loss of $0.16, vs. FactSet Est of $0.17 Loss

MT Newswires Live
·
Nov 04